D Paul Harkin

List of Publications by Year
in descending order

61	8,568	116194	145109
papers	citations	36 h-index	60 g-index

62	62	62	15348
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. British Journal of Cancer, 2022, 126, 247-258.	2.9	14
2	Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors. Cancer Research, 2022, 82, 819-830.	0.4	16
3	Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification. Clinical Cancer Research, 2022, 28, 3546-3556.	3.2	5
4	High EMSY expression defines a BRCAâ€like subgroup of highâ€grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. Cancer, 2019, 125, 2772-2781.	2.0	28
5	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. Gut, 2019, 68, 1918-1927.	6.1	18
6	Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer. Laboratory Investigation, 2018, 98, 15-26.	1.7	81
7	Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment. BMJ Open, 2018, 8, e023115.	0.8	3
8	Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. Oncotarget, 2018, 9, 4722-4736.	0.8	22
9	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. European Urology, 2017, 72, 509-518.	0.9	26
10	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw199.	3.0	338
11	The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export. Nucleic Acids Research, 2017, 45, 12816-12833.	6.5	79
12	Dual roles of <scp>DNA</scp> repair enzymes in <scp>RNA</scp> biology/postâ€transcriptional control. Wiley Interdisciplinary Reviews RNA, 2016, 7, 604-619.	3.2	19
13	Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line. Nucleic Acids Research, 2016, 44, e137-e137.	6.5	20
14	The identification of a novel role for BRCA1 in regulating RNA polymerase I transcription. Oncotarget, 2016, 7, 68097-68110.	0.8	15
15	The molecular and genetic basis of inherited cancer risk inÂgynaecology. The Obstetrician and Gynaecologist, 2015, 17, 233-241.	0.2	8
16	Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM. Cancer Research, 2015, 75, 2159-2165.	0.4	58
17	PICan: An integromics framework for dynamic cancer biomarker discovery. Molecular Oncology, 2015, 9, 1234-1240.	2.1	15
18	Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. Modern Pathology, 2015, 28, 428-436.	2.9	27

#	Article	IF	Citations
19	<scp>BRCA</scp>1, a â€˜complexâ€™ protein involved in the maintenance of genomic stability. FEBS Journal, 2015, 282, 630-646.	2.2	141
20	Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention. Oncotarget, 2015, 6, 43244-43254.	0.8	8
21	Identification and Validation of an Anthracycline/Cyclophosphamideâ€“Based Chemotherapy Response Assay in Breast Cancer. Journal of the National Cancer Institute, 2014, 106, djt335.	3.0	91
22	NF-ÎºB is a critical mediator of BRCA1-induced chemoresistance. Oncogene, 2014, 33, 713-723.	2.6	41
23	The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology, 2014, 65, 340-352.	1.6	59
24	BRCA1 Deficiency Exacerbates Estrogen-Induced DNA Damage and Genomic Instability. Cancer Research, 2014, 74, 2773-2784.	0.4	94
25	Identification of a BRCA1-mRNA Splicing Complex Required for Efficient DNA Repair and Maintenance of Genomic Stability. Molecular Cell, 2014, 54, 445-459.	4.5	146
26	Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab.. Journal of Clinical Oncology, 2014, 32, 5502-5502.	0.8	71
27	TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.. Oncotarget, 2014, 5, 1609-1620.	0.8	37
28	BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers. Nucleic Acids Research, 2013, 41, 8601-8614.	6.5	44
29	Implications for Powering Biomarker Discovery Studies. Journal of Molecular Diagnostics, 2012, 14, 130-139.	1.2	7
30	BRCA1 is an essential mediator of vinorelbineâ€induced apoptosis in mesothelioma. Journal of Pathology, 2012, 227, 200-208.	2.1	33
31	BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecologic Oncology, 2011, 123, 492-498.	0.6	62
32	PARP inhibition induces BAX/BAKâ€independent synthetic lethality of BRCA1â€deficient nonâ€small cell lung cancer. Journal of Pathology, 2011, 224, 564-574.	2.1	32
33	The Î”Np63 Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer. Cancer Research, 2011, 71, 1933-1944.	0.4	35
34	Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue. Journal of Clinical Oncology, 2011, 29, 4620-4626.	0.8	178
35	Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. Nucleic Acids Research, 2011, 39, 9536-9548.	6.5	43
36	BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Research and Treatment, 2010, 122, 721-731.	1.1	68

#	Article	IF	Citations
37	BRD7, a Subunit of SWI/SNF Complexes, Binds Directly to BRCA1 and Regulates BRCA1-Dependent Transcription. Cancer Research, 2010, 70, 2538-2547.	0.4	115
38	Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. Oncologist, 2010, 15, 390-404.	1.9	155
39	The Complex Relationship between BRCA1 and ERÎ± in Hereditary Breast Cancer. Clinical Cancer Research, 2009, 15, 1514-1518.	3.2	58
40	BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecologic Oncology, 2009, 113, 134-142.	0.6	78
41	BRCA1 and BRCA2: Role in the DNA Damage Response, Cancer Formation and Treatment. , 2009, , 415-443.		2
42	RNA expression analysis from formalin fixed paraffin embedded tissues. Histochemistry and Cell Biology, 2008, 130, 435-445.	0.8	169
43	Generation of a non-small cell lung cancer transcriptome microarray. BMC Medical Genomics, 2008, 1, 20.	0.7	18
44	BRCA1 , a Potential Predictive Biomarker in the Treatment of Breast Cancer. Oncologist, 2007, 12, 142-150.	1.9	146
45	BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy. Clinical Cancer Research, 2007, 13, 7413-7420.	3.2	200
46	BRCA1 Regulates IFN-Î³ Signaling through a Mechanism Involving the Type I IFNs. Molecular Cancer Research, 2007, 5, 261-270.	1.5	44
47	Molecular Basis for Estrogen Receptor Â Deficiency in BRCA1-Linked Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 1683-1694.	3.0	183
48	BRCA1â€"A good predictive marker of drug sensitivity in breast cancer treatment?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 205-216.	3.3	25
49	Genomics and the Impact of New Technologies on the Management of Colorectal Cancer. Oncologist, 2006, 11, 988-991.	1.9	5
50	The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-Î³-mediated apoptosis. Oncogene, 2005, 24, 5492-5501.	2.6	53
51	BRCA1 and c-Myc Associate to Transcriptionally Repress Psoriasin, a DNA Damageâ€"Inducible Gene. Cancer Research, 2005, 65, 10265-10272.	0.4	76
52	BRCA1 Interacts with and Is Required for Paclitaxel-Induced Activation of Mitogen-Activated Protein Kinase Kinase Kinase 3. Cancer Research, 2004, 64, 4148-4154.	0.4	46
53	The Role of BRCA1 in the Cellular Response to Chemotherapy. Journal of the National Cancer Institute, 2004, 96, 1659-1668.	3.0	399
54	The biology of breast carcinoma. Cancer, 2003, 98, 1327-1328.	2.0	1

#	Article	IF	Citations
55	5-Fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 2003, 3, 330-338.	12.8	4,015
56	BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Research, 2003, 63, 6221-8.	0.4	339
57	BRCA1 Regulates the Interferon Î³-mediated Apoptotic Response. Journal of Biological Chemistry, 2002, 277, 26225-26232.	1.6	60
58	BRCA1 : mechanisms of inactivation and implications for management of patients. Lancet, The, 2002, 360, 1007-1014.	6.3	115
59	The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Research, 2002, 62, 2644-9.	0.4	82
60	BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene, 2001, 20, 6123-6131.	2.6	154
61	Uncovering Functionally Relevant Signaling Pathways Using Microarrayâ€Based Expression Profiling. Oncologist, 2000, 5, 501-507.	1.9	47